Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 53 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel Jr EF, Grijalva CG. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case-control study. Ann Intern Med 2018;168:396-404. [Ref.ID 102563]
2. Cita con resumen
Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med 2016;164:705-14. [Ref.ID 100414]
3.Tiene citas relacionadas Cita con resumen
Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Insulin vs sulfonlylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014;311:2288-96. [Ref.ID 97697]
4.Tiene citas relacionadas Cita con resumen
Griffin MR. High-dose non-steroidal anti-inflammatories: painful choices. Lancet 2013;382:746-8. [Ref.ID 95994]
5. Cita con resumen
Griffin MR, Zhu Y, Moore MR, Withney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013;369:155-63. [Ref.ID 95819]
6.Tiene citas relacionadas Cita con resumen
Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012;157:601-10. [Ref.ID 94011]
7.Enlace a cita original Cita con resumen
Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lfthus G, Meece JK, Williams JV, Berman L, Breese HC, Monto AS, Griffin MR, Belongia E, Shay DK, for the US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012;55:951-9. [Ref.ID 93145]
8.Tiene citas relacionadas Cita con resumen
Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-a antagonists and the risk of hospitalization for infections in patients with autoimmune diseases. JAMA 2011;306:2331-9. [Ref.ID 91921]
9.Tiene citas relacionadas Cita con resumen
Grijalva CG, Chen L, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-alfa antagonists and the risk of hospitalization for infection in patients with autoimmune diseses. JAMA 2011;306:2331-9. [Ref.ID 91686]
10. Cita con resumen
Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors. A cohort study. Ann Intern Med 2010;152:337-45. [Ref.ID 88125]
11.Enlace a cita originalTiene citas relacionadas
Roumie CL, Choma NN, Kaltenbach L, Mitchel Jr EF, Arbogast PG, Griffin MR. Non-aspirin NSAIDs, cycloxygenase-2 inhibitors and risk for cardiovascular events - Stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 2009;18:1053-63. [Ref.ID 87051]
12. Cita con resumen
Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009;302:758-66. [Ref.ID 86570]
13. Cita con resumen
Hall CB, Weinberg GA, Iwane M, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2008;360:588-98. [Ref.ID 85167]
14.Enlace a cita original
Grijalva CG, Chung CP, Stein CM, Gideon PS, Dyer SM, Mitchel Jr EF, Griffin MR. Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis. Pharmacoepidemiol Drug Saf 2008;17:890-5. [Ref.ID 83995]
15. Cita con resumen
Roumie CL, Mitchel Jr EF, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008;39:2037-45. [Ref.ID 83569]
16.
Gaba PD, Haley C, Griffin MR, Mitchel E, Warkentin J, Holt E, Baggett P, Sterling TR. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007;167:2317-22. [Ref.ID 81640]
17.Tiene citas relacionadas
Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369:1179-86. [Ref.ID 79755]
18. Cita con resumen
Ray W A, Griffin MR, Stein CM. Cardiovascular toxicity of valdecoxib. N Engl J Med 2004;351:2767. [Ref.ID 72547]
19. Cita con resumen
Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray W A. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 2004;13:339-43. [Ref.ID 70400]
20.Tiene citas relacionadas
Edwards KM, Griffin MR. Great expectations for a new vaccine. N Engl J Med 2003;349:1312-4. [Ref.ID 67712]
Seleccionar todas
 
 1 a 20 de 53 siguiente >>